Sicca Syndrome (Sjogren) - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Sicca Syndrome (Sjogren) - Pipeline Review, H1 2018’, provides an overview of the Sicca Syndrome (Sjogren) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sicca Syndrome (Sjogren)

- The report reviews pipeline therapeutics for Sicca Syndrome (Sjogren) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Sicca Syndrome (Sjogren) therapeutics and enlists all their major and minor projects

- The report assesses Sicca Syndrome (Sjogren) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Sicca Syndrome (Sjogren)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Sicca Syndrome (Sjogren)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Sicca Syndrome (Sjogren) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akari Therapeutics Plc

Amgen Inc

Atlantic Bio Sci LLC

Bristol-Myers Squibb Co

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Galapagos NV

Gilead Sciences Inc ...

Akari Therapeutics Plc

Amgen Inc

Atlantic Bio Sci LLC

Bristol-Myers Squibb Co

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Galapagos NV

Gilead Sciences Inc

GlaxoSmithKline Plc

Immunwork Inc

MimeTech Srl

Novartis AG

Ono Pharmaceutical Co Ltd

OSE Immunotherapeutics

Samjin Pharm Co Ltd

TearSolutions LLC

XTL Biopharmaceuticals Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Sicca Syndrome (Sjogren) – Overview

Sicca Syndrome (Sjogren) – Therapeutics ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Sicca Syndrome (Sjogren) – Overview

Sicca Syndrome (Sjogren) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Sicca Syndrome (Sjogren) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sicca Syndrome (Sjogren) – Companies Involved in Therapeutics Development

Akari Therapeutics Plc

Amgen Inc

Atlantic Bio Sci LLC

Bristol-Myers Squibb Co

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Galapagos NV

Gilead Sciences Inc

GlaxoSmithKline Plc

Immunwork Inc

MimeTech Srl

Novartis AG

Ono Pharmaceutical Co Ltd

OSE Immunotherapeutics

Samjin Pharm Co Ltd

TearSolutions LLC

XTL Biopharmaceuticals Ltd

Sicca Syndrome (Sjogren) – Drug Profiles

abatacept – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABS-11 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-557 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

belimumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

belimumab + rituximab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Type 1 Diabetes and Sjogrens Syndrome – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CFZ-533 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coversin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edratide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgotinib – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-9876 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lacripep – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leniolisib – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit INFA for Systemic Lupus Erythematosus and Sjogren Syndrome – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-8 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSE-127 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7625 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSLV-132 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SA-001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TE-2324 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tibulizumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tirabrutinib – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAY-736 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIB-4920 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIB-7734 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VM-200 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sicca Syndrome (Sjogren) – Dormant Projects

Sicca Syndrome (Sjogren) – Discontinued Products

Sicca Syndrome (Sjogren) – Product Development Milestones

Featured News & Press Releases

Sep 12, 2017: XTL Biopharmaceuticals Unveils Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's Syndrome

Apr 05, 2017: XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjogren’s Syndrome

Apr 04, 2017: Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib

Feb 13, 2017: XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's syndrome

Jan 05, 2017: XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjogren's Syndrome

Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogren’s syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Sicca Syndrome (Sjogren), H1 2018

Number of Products under Development by Companies, H1 2018

Number of ...

List of Tables

Number of Products under Development for Sicca Syndrome (Sjogren), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Sicca Syndrome (Sjogren) – Pipeline by Akari Therapeutics Plc, H1 2018

Sicca Syndrome (Sjogren) – Pipeline by Amgen Inc, H1 2018

Sicca Syndrome (Sjogren) – Pipeline by Atlantic Bio Sci LLC, H1 2018

Sicca Syndrome (Sjogren) – Pipeline by Bristol-Myers Squibb Co, H1 2018

Sicca Syndrome (Sjogren) – Pipeline by Eli Lilly and Co, H1 2018

Sicca Syndrome (Sjogren) – Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Sicca Syndrome (Sjogren) – Pipeline by Galapagos NV, H1 2018

Sicca Syndrome (Sjogren) – Pipeline by Gilead Sciences Inc, H1 2018

Sicca Syndrome (Sjogren) – Pipeline by GlaxoSmithKline Plc, H1 2018

Sicca Syndrome (Sjogren) – Pipeline by Immunwork Inc, H1 2018

Sicca Syndrome (Sjogren) – Pipeline by MimeTech Srl, H1 2018

Sicca Syndrome (Sjogren) – Pipeline by Novartis AG, H1 2018

Sicca Syndrome (Sjogren) – Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

Sicca Syndrome (Sjogren) – Pipeline by OSE Immunotherapeutics, H1 2018

Sicca Syndrome (Sjogren) – Pipeline by Samjin Pharm Co Ltd, H1 2018

Sicca Syndrome (Sjogren) – Pipeline by TearSolutions LLC, H1 2018

Sicca Syndrome (Sjogren) – Pipeline by XTL Biopharmaceuticals Ltd, H1 2018

Sicca Syndrome (Sjogren) – Dormant Projects, H1 2018

Sicca Syndrome (Sjogren) – Dormant Projects, H1 2018 (Contd..1), H1 2018

Sicca Syndrome (Sjogren) – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Sicca Syndrome (Sjogren), H1 2018

Number of Products under Development by Companies, H1 2018

Number of ...

List of Figures

Number of Products under Development for Sicca Syndrome (Sjogren), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports